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Irreversible Inhibition of CD13/Aminopeptidase N
by the Antiangiogenic Agent Curcumin
APN in tumor invasion revealed that the metalloprotease
cleaves certain extracellular matrix proteins, including
type IV collagen and some components of Matrigel [4, 5].
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[6, 7]. These data indicate that APN plays a critical role
in angiogenesis. Accordingly, APN is considered an im-
portant therapeutic target for tumor angiogenesis andSummary
metastasis. Based on this idea, an extensive screening
was carried out to discover functional inhibitors of APNCD13/aminopeptidase N (APN) is a membrane-bound,
from natural products and chemical libraries [8, 9]. Here,zinc-dependent metalloproteinase that plays a key
we have identified curcumin and its derivatives as novelrole in tumor invasion and angiogenesis. Here, we
inhibitors of APN.show that curcumin, a phenolic natural product, binds
to APN and irreversibly inhibits its activity. The direct Curcumin (Figure 1) is a phenolic natural product
interaction between curcumin with APN was con- isolated from the rhizome of Curcuma longa (turmeric).
firmed both in vitro and in vivo by surface plasmon It consists of two vinylguaiacol groups joined by a
resonance analysis and an APN-specific antibody com- -diketone unit. Previous studies have shown that cur-
petition assay, respectively. Moreover, curcumin and cumin strongly inhibited the initiation and promotion of
other known APN inhibitors strongly inhibited APN- chemical carcinogen-induced tumor formation in mice
positive tumor cell invasion and basic fibroblast growth [10, 11] and the proliferation of various cultured tumor
factor-induced angiogenesis. However, curcumin did cells [12–14]. These potent chemopreventive activities
not inhibit the invasion of APN-negative tumor cells, of curcumin may be attributed to the inhibition of certain
suggesting that the antiinvasive activity of curcumin signal transduction pathways critical for tumor cell
against tumor cells is attributable to the inhibition of growth, such as AP-1, NF-B, and protein kinase C
APN. Taken together, our study revealed that curcumin [15–17].
is a novel irreversible inhibitor of APN that binds to Recently, curcumin was shown to inhibit the prolifera-
curcumin resulting in inhibition of angiogenesis. tion of human umbilical vein endothelial cells (HUVECs)
and to reduce the expression of matrix metalloprotei-
nase-9 (MMP-9) [18, 19]. Moreover, curcumin inhibitedIntroduction
corneal neovascularization without inhibiting TPA-induced
CD13 (gp150), a myeloid cell surface glycoprotein, is secretion of vascular endothelial growth factor (VEGF)
identical to aminopeptidase N (APN), an ectoenzyme [20]. These studies demonstrate that the potent chemo-
which can cleave bioactive proteins on the cell surface, preventive activity of curcumin may, in part, be derived
including several cytokines [1]. It is involved in the down- from the direct inhibition of in vivo angiogenesis. How-
regulation of signal peptides, such as enkephalines [2]. ever, the mechanism of angiogenesis inhibition by cur-
Various studies have shown that APN, as a zinc-depen- cumin has not been fully understood yet.
dent metalloproteinase, plays an important role in meta- Here, we show that curcumin strongly inhibits APN
static tumor cell invasion [3, 4]. The stable transfection of activity both in vitro and in vivo and directly binds to APN
melanoma cells with full-length APN cDNA significantly in vitro and in HUVECs. The inhibition of APN activity by
increased the invasiveness of the cells. A good correla- curcumin resulted in a dose-dependent suppression of
tion between the invasiveness index and APN expres- tumor invasion of APN-positive cells and of bFGF-
sion levels was demonstrated [3]. Functional studies on induced angiogenic differentiation of HUVECs. These
results demonstrate that APN is an important target of
curcumin for its antiangiogenic activity.*Correspondence: kwonhj@sejong.ac.kr
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Figure 1. Structures of Compounds
(A) Curcumin and demethoxycurcumin were
purified from commercial curcuminoids using
thin layer chromatography.
(B) Hydrazinocurcumin is a new synthetic de-
rivative of curcumin.
(C) Bestatin is a competitive inhibitor of APN.
Results mixture was filtered using a Microcon-YM30 filter, which
can retain proteins higher than 30 kDa molecular weight.
The retained protein in the upper part of the Microcon-Curcumin Potently Inhibits APN Enzymatic
Activity In Vitro and In Vivo YM30 filter was resuspended in PBS and examined for
APN activity. The APN activity of drug-untreated controlThe screening of APN inhibitors was carried out using
3000 compounds from natural products and the chemi- was normalized to 100% of the enzyme activity. The
activity of bestatin-treated APN increased during subse-cal library in our laboratory. A final concentration of 10
g/ml of each library was inoculated into each well of quent filtration and reached about 100% of the control
enzyme activity after three filtrations (Figure 3A). How-a black 96-well plate, and high-throughput screening
was carried out by fluorescence measurement. In the ever, the enzymatic activity of curcumin-treated APN
was not restored even after three filtrations. These datacourse of the screening, curcumin was presently identi-
fied as a potent inhibitor of APN. Curcumin and its deriv- suggest that the inhibition of APN by curcumin is irre-
versible and that the mode of inhibition of APN by cur-atives (Figure 1), including demethoxycurcumin, hydra-
zinocurcumin, and bestatin, a known APN inhibitor, were cumin is different from that of bestatin, which is a re-
versible, competitive inhibitor. To further confirm thetested for their ability to block APN activity in vitro.
Curcumin and demethoxycurcumin potently inhibited irreversibility of enzyme inhibition by curcumin, a kinetic
graph (EV plot) of the initial velocity versus enzyme con-the activity of APN with IC50 values of 10 and 20 M,
respectively, while hydrazinocurcumin, a synthetic ana- centrations was plotted. This plot has been previously
used to confirm the irreversibility of the inhibition oflog of curcumin in which the central -diketone moiety
was substituted by pyrazole, did not inhibit the enzyme mammalian histone deacetylase (HDAC) by trapoxin, an
antitumor cyclic tetrapeptide [22]. A similar result wasactivity (IC50  100 M) (Figure 2A). Among the tested
compounds, bestatin showed the most potent inhibitory obtained from the EV plots for curcumin and APN. As
shown in Figure 3B, the enzyme activity of the controlactivity against APN enzymatic activity (IC50  2.5 M).
The inhibition of APN by curcumin is noncompetitive group increased in proportion to the amount of enzyme
added. Treatment with 10 M bestatin inhibited the en-(Ki  11.2 M; Figure 2B). In vivo enzyme assays were
carried out by monitoring the enzymatic degradation of zyme activity at a constant ratio depending on the en-
zyme concentration. In contrast, 10 M of curcumina fluorescent substrate using cultured cells as a source
of enzyme. The in vivo specificity of the substrates, inhibited the enzyme activity by a fixed extent irrespec-
tive of the enzyme concentrations, leading to a parallelincluding ala-pNA and ala-7-amido-4-methylcoumarin,
toward aminopeptidase N was previously demonstrated shift of the EV plot line from the control line toward the
right. These data suggest that a fixed amount of APN,[4, 21]. Curcumin inhibited the enzymatic activity of APN
both in HUVECs and in APN-positive HT1080 cells with corresponding to the amount of curcumin, was irrevers-
ibly inhibited.IC50 values of 10 and 7 M, respectively (Figures 2C and
2D). In the latter two assays, curcumin was more potent
than bestatin, which had an IC50 value of 20 and 13 M. Analysis of the Interaction between Curcumin
These data demonstrate that curcumin is a noncompeti- and APN In Vitro and In Vivo
tive inhibitor of APN. In vitro interaction of curcumin with APN was investi-
gated using surface plasmon resonance analysis. A
strong binding curve was observed when curcumin wasInhibition of APN Activity by Curcumin
Is Irreversible applied to immobilized APN on the CM5 sensor chip
(Figure 4A). As much as 100 M hydrazinocurcumin, anWe next examined the kinetics of curcumin inhibition of
APN activity. For the assay, purified APN was incubated inactive curcumin derivative, however, did not bind to
APN. Using BIAcore evaluation software, the kinetic pa-with either curcumin or bestatin, and then the reaction
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Figure 2. The Effect of Curcumin Derivatives
on APN Activity
(A) In vitro APN assay using purified amino-
peptidase N.
(B) Kinetic analysis of enzyme inhibition by
curcumin using Lineweaver-Burk plot of APN.
Dixon plot was used to determine the Ki value
(Ki  11.2 M).
(C and D) In vivo enzyme assay of APN in
HUVECs (C) and in HT1080 (D) cells, respec-
tively. Each value represents mean SE from
three independent experiments. Cur, cur-
cumin; D-Cur, demethoxycurcumin; H-Cur,
hydrazinocurcumin; Best, bestatin.
rameters of ka, kd, and KD were measured. There was a APN negative did not change their fluorescence level
(Figure 4Db). These data demonstrate that curcuminvery low dissociation rate (kd) of 2.92 105 s1, whereas
the association rate (ka) was 2.98 M1 s1. The apparent directly binds to APN both in vitro and in vivo with high
affinity and inhibits its enzymatic activity.dissociation constant (KD) of curcumin binding to APN
was calculated as 9.8  106 M. In addition, the steady-
state affinity data for curcumin were obtained from the Curcumin Inhibits bFGF-Induced Angiogenesis
Specific inhibition of APN activity has previously beensoftware. Steady-state binding levels (Req) of each cur-
cumin concentration were plotted, and the saturation shown to suppress angiogenesis both in vitro and in
vivo [6, 7]. Therefore, we examined the effects of cur-curve was obtained from the plot (Figure 4B). Saturation
of binding was observed from 50 M of curcumin to cumin and bestatin on angiogenesis. First, we investi-
gated the time- and dose-response of curcumin onAPN immobilized on a CM5 sensor chip. Next, we inves-
tigated the interaction of curcumin with APN in HUVECs. HUVEC growth. Curcumin inhibited the proliferation of
HUVECs in a time- and dose-dependent manner (FigureTo investigate the binding capacity of curcumin to APN
in vivo, HUVECs treated with either curcumin or hydra- 5A). Cytotoxicity was not observed at 15 M treatment
for 72 hr. Thus, all angiogenesis assays were conductedzinocurcumin were harvested with EDTA and subse-
quently labeled with WM15, an antibody specific for at the concentration range of 1 to 15 M within 72 hr.
We then examined the effects of APN inhibitors on angi-human APN [23]. Antibody-labeled cells were then incu-
bated with FITC-conjugated anti-mouse IgG and sub- ogenesis using in vitro invasion and tube formation
assays. Curcumin and bestatin inhibited bFGF-inducedjected to fluorescent activated cell sorting (FACS) analy-
sis. Control, untreated cells exhibited a high level of invasion (Figure 5B) and capillary tube formation of
HUVECs (Figures 5Cb, 5Cc [white arrow], and 5Cd) in afluorescence, shown as a dramatic shift in curves (Figure
4Ca, black arrow). However, 10 M of curcumin signifi- dose-dependent manner. Cytotoxicity was not ob-
served in tube formation assay as confirmed by trypancantly reduced the fluorescence level of HUVECs la-
beled with the antibody (Figure 4Cb). The competition blue staining (data not shown). Furthermore, in vivo en-
dogenous neovascularization of the chick embryonicof curcumin with the antibody for the binding to APN is
dose dependent (Figures 4Ca, 4Cb, and 4Cc). We then chorioallantoic membrane was significantly blocked by
curcumin without showing rupture of preexisting vesselsinvestigated the effect of hydrazinocurcumin, an inactive
curcumin derivative, on the competition of antibody (Figure 5D). Negligible toxicity toward eggs was ob-
served after curcumin treatment, indicating that the com-binding to APN. Though hydrazinocurcumin is very simi-
lar to curcumin in structure and hydrophobicity, it did pound is a promising, nontoxic antiangiogenic agent.
not change the level of fluorescence even at 50 M
treatment (Figure 4Cd). These data imply that the inter- Analysis of APN Expression and Tumor
Cell Invasionaction between curcumin and APN is specific. The spec-
ificity of antibody (WM15) to APN was verified using We then examined the expression of APN in HUVECs
to determine whether its expression is regulated withtwo different cell lines, HT1080 and MDA-MB-231 cells.
HT1080 cells showed a high binding affinity with the angiogenic differentiation induced by bFGF. RT-PCR
analysis showed that bFGF significantly increased theantibody (Figure 4Da), while MDA-MB-231 cells that are
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231, breast cancer cells, showed relatively low amounts
or absence of APN expression. Several investigations
suggest that APN plays a pivotal role in tumor metasta-
sis, which is supported by reports that several APN
inhibitors, including bestatin, actinonin, amastatin, and
homophthalimide, blocked metastatic tumor cell inva-
sion [5, 24, 25]. The relationship between APN expres-
sion and cell invasive activity was investigated. The rela-
tive invasiveness of each tumor cell was determined by
comparison with that of HT1080 cells used as a normali-
zation control (100%). The results revealed that APN-
expressing C8161 and B16/BL6 cells were highly invasive,
while HT29 and HCT116 cells that were APN negative
showed relatively low invasive activities (Figure 6D). In
contrast, breast cancer cells were highly invasive, even
though they showed low amounts of APN expression
or were APN negative. Since the degradation of the
extracellular matrix involves several proteases, includ-
ing matrix metalloproteinases, serine proteases, and
aminopeptidases, the invasiveness of breast cancer
cells seems to be APN independent [26].
Curcumin Inhibits Tumor Invasion of APN-Positive
Cells but Does Not Affect an APN-Negative Cell Line
We finally examined the functional significance of APN
inhibition by curcumin using two cell lines showing dif-
ferent expression levels of APN. APN-positive (C8161)
and -negative (MDA-MB-231) tumor cells were used to
investigate the effect of curcumin on the invasiveness of
the cells. Both cell lines were highly invasive, as shown in
Figure 6D. Interestingly, C8161 cell invasion was signifi-
cantly inhibited by curcumin, whereas that of MDA-MB-
231 cells was not (Figure 7A). The inhibition of the inva-
sion of C8161 cells occurred at a concentration of 5 M
(Figure 7), which was found to inhibit the enzymaticFigure 3. Reversibility and Kinetic Analysis of APN Inhibition by Cur-
activity of APN (Figure 2). In addition, tumor invasion ofcumin
all three APN-positive cells was significantly inhibited(A) Reversibility of enzyme inhibition. Purified porcine APN was incu-
by curcumin without showing any cytotoxicity at thebated with 0.5% methanol (Control), 10 M bestatin (Best), and 10
M curcumin (Cur) for 2 hr. The enzyme reaction solutions were same concentration (Figure 7B). These results suggest
filtered using Microcon-YM30, and the activity of the residual en- that curcumin inhibits the invasion of APN-positive cells,
zyme resuspended in PBS was determined. The white bars repre- at least in part, through the inhibition of the enzymatic
sent the enzymatic activity of APN before the filtration. The hatched
activity of APN.and black bars represent the enzymatic activity of APN after the
filtration one and three times, respectively. The APN activity of drug-
untreated control was normalized to 100%, and drug-treated en- Discussion
zyme activity was expressed as a percentage of inhibition versus
control. The data represent mean  SE from three independent
Curcumin is a potent chemopreventive agent that hasexperiments. *, p	 0.0001 versus control APN activity (before filtra-
been entered into phase I clinical trials for cancer che-tion); #, p 	 0.0004 versus control APN activity (after filtration three
times). moprevention by the National Cancer Institute, NIH,
(B) Kinetics analysis of enzyme inhibition. The enzymatic activity of Bethesda, MD [27]. Many other groups also reported
APN was determined as described in Experimental Procedures. The phase I clinical trials of curcumin and showed promising
kinetics of enzyme inhibition by bestatin (Best) or curcumin (Cur) is
results, i.e., curcumin is pharmacologically safe and haspresented as an EV plot of initial velocity versus enzyme concentra-
enormous potential in the prevention and therapy oftions.
cancer [28–30]. Because its chemopreventive activities
have been observed at various tumor types [10, 11], it
has been postulated that the potent chemopreventiveexpression level of APN in HUVECs (Figures 6A and 6B),
in agreement with a previous report by Bhagwat et al. activity of curcumin may be, in part, the result of a direct
inhibition of angiogenesis [20], which would be widely[7]. Various tumor cell lines were also investigated to
determine the expression level of APN. As shown in effective on the growth of tumors in vivo [31]. However,
the molecular basis for the precise mechanism of angio-Figure 6C, C8161, a human melanoma, HT1080, a human
fibrosarcoma, and B16/BL6, a murine melanoma, showed genesis inhibition by curcumin has not yet been eluci-
dated.high levels of APN expression, whereas HT29 and
HCT116, colon carcinomas, and MCF-7 and MDA-MB- In the present study, we found that curcumin binds
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Figure 4. Analysis of the Interaction Between Curcumin and APN In Vitro and In Vivo
(A) The binding sensorgram of the curcumin and hydrazinocurcumin on APN from BIAcore analysis. Sensorgrams were obtained for 4 M
(bold dotted line), 16 M (bold broken line), and 50 M (bold line) of curcumin, 100 M of hydrazinocurcumin (thin broken line), and 5% DMSO
in flow buffer (thin line) against APN immobilized on the sensor chip.
(B) The plot of steady-state binding level (Req) against the concentration of curcumin. Each value was obtained from the equation as described
in Experimental Procedures.
(C) FACS analysis of the competitive binding of curcumin with APN-specific antibody (WM15) to HUVECs. The curves indicated by white
arrows represent HUVECs incubated with FITC-conjugated anti-mouse IgG only. Black arrows indicate the curves for HUVECs labeled with
WM15 followed by FITC-conjugated anti-mouse IgG. Curves were obtained from antibody-labeled HUVECs incubated with 0 M (a), 10 M
(b), and 50 M (c) of curcumin and 50 M of hydrazinocurcumin (d).
(D) The binding of WM15 to APN in either HT1080 (APN-positive) or MDA-MB-231 (APN-negative) cells. Note the increased fluorescence in
HT1080 (a) but not in MDA-MB-231 cells (b).
to APN and irreversibly inhibits its activity. The direct including cysteine, dithiothreitol, and -mercapto-
ethanol, are known to cause the reduction of curcumin,interaction between curcumin and APN was confirmed
in vitro and in vivo by surface plasmon resonance analy- and reduced curcumin could not inhibit the activation of
protein kinase C [17]. Protein kinase C contains cysteinesis and an antibody competition assay. However, the
mode of binding of curcumin to APN has not yet residues located in its regulatory domain, which may
form an adduct with the 
, -unsaturated ketones ofbeen determined. Several studies suggest that 
,
-unsaturated ketones of curcumin are crucial for the curcumin [17]. In addition, human glutathione S-trans-
ferase P1-1 (GSTP1-1) is irreversibly inhibited by cur-binding to its target proteins. Various thiol compounds,
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Figure 5. Inhibition of Angiogenesis Activities by Curcumin and Bestatin
(A) Time and dose responses of curcumin on HUVECs. HUVECs were treated with curcumin, and cell growth was determined at various time
points. The absorbance of MTT-formazan (540 nm, y axis) represents cell growth. Each value represents mean  SE from three independent
experiments.
(B) The effects of curcumin and bestatin on the bFGF-induced invasion of HUVECs. Serum-starved HUVECs in serum-free medium (SF) or
treated with bFGF in the presence or absence of inhibitors were used for invasion assay. The invasiveness of cells in SF was used as a
normalization control (100%). Each value represents the mean  SE from three independent experiments. *, p 	 0.03; **, p 	 0.007; and #,
p 	 0.02 versus bFGF control.
(C) The effects of curcumin and bestatin on capillary tube formation of HUVECs. HUVECs with 30 ng/ml of bFGF (a), bFGF and 5 M curcumin
(b), bFGF and 10 M curcumin (c), and bFGF and 100 M bestatin (d). White arrows indicate the inhibition of tube networks by the agents.
(D) Inhibition of angiogenesis by curcumin in the CAM assay. Retinoic acid (RA, 1 g/egg) and curcumin (Cur, 10 g/egg) were applied to the
CAM assay, and the inhibition ratio was calculated based on the percentage of angiogenic eggs to total numbers of eggs tested.
cumin through the Michael addition of the Cys47 residue In our study, the reduction of curcumin by thiol com-
pounds, particularly by cysteine, completely blockedin GSTP1-1 with 
, -unsaturated ketones of the com-
pound [32]. Interestingly, the M1 family of zinc metallo- the inhibitory activity of curcumin against APN (data
not shown). Thus, we postulate that 
, -unsaturatedpeptidases, including pig APN, human APN, human
aminopeptidase A (APA), rat aminopeptidase B (APB), ketones of curcumin may be covalently linked to nucleo-
philic amino acid residues in the active site of APN.and mouse puromycin-sensitive aminopeptidase (PSA),
have four highly conserved domains in the active site To investigate a possible binding mode of curcumin
and its derivatives to APN, flexible dockings were con-of the enzymes [33]. These conserved domains contain
two nucleophilic amino acid residues, Cys218 and Lys225. ducted using the FlexX program implanted in Sybyl 6.8
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Figure 6. Analysis of APN Expression and
Tumor Invasion
(A) RT-PCR analysis of APN expression in
HUVECs. HUVECs were stimulated by bFGF
(30 ng/ml), and RNA was isolated at the indi-
cated time points. The isolated RNA was con-
verted to cDNA in the presence or absence
(No RT) of reverse transcriptase. Standard
RT-PCR was performed using the primer pair
specific for APN with or without (No Temp)
cDNA template. The level of -actin mRNA
was used as an internal control. M denotes
size marker.
(B) Quantitative data for RT-PCR results. The
expression level of APN mRNA was deter-
mined by densitometry. Each value repre-
sents mean SE from three independent ex-
periments. *, p 	 0.04; **, p 	 0.0004 versus
bFGF (0 hr).
(C) APN expression in cultured tumor cell
lines using RT-PCR with primers common to
murine and human APN. The level of glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH)
mRNA was used as an internal control.
(D) Relative invasiveness of various tumor cell
lines. The invasiveness of each cell line was
determined by the ratio of the number of in-
vaded cells to total inoculated cells. Relative
invasiveness of each cell line was calculated
by the comparison with the invasiveness of
HT1080 cells that were used as a normaliza-
tion control (100%). Tumor invasion assay
was performed as described in Experimental
Procedures. Each value represents mean 
SE from three independent experiments. *,
p 	 0.0001; #, p 	 0.0002 versus HT1080
control.
(Tripos Inc.) (J. Lee, J.S.S, H.-J.P., and H.J.K, unpub- the invasion of APN-positive tumor cells and growth
factor-induced angiogenesis of endothelial cells at thelished results). The active site of bovine lens leucine
aminopeptidase (blLAP, EC.3.4.11.1), the only amino- same concentration at which the inhibition of APN activ-
ity occurred. However, the invasion of APN-negativepeptidase for which an X-ray structure is available [34],
was introduced into the docking study. In enzyme breast cancer cells was not inhibited by curcumin. These
data suggest that APN is a direct target of curcumin forassays, the activity of blLAP was inhibited by curcumin
similar to the level observed with APN (data not shown). its antiinvasive activity. Considering that endothelial cell
invasion is an essential step for angiogenesis, the anti-In docking studies, curcumin snugly fits into the catalytic
pocket of blLAP. The active site of blLAP contains two angiogenic activity of curcumin is also through, in part,
the inhibition of APN activity. However, we cannot ex-lysine residues (Lys250 and Lys262) that may form an ad-
duct with curcumin through Michael addition or Schiff- clude the possibility that curcumin still affects other
known cellular targets, such as PKC and Ca2-ATPasebase formation. In contrast, hydrazinocurcumin, a con-
formationally rigid derivative, fails to be accommodated [35], and certain signal transduction pathways that are
possibly involved during the complex process of angio-into the catalytic pocket of blLAP, based on data show-
ing that hydrazinocurcumin fails to inhibit APN activity. genesis [15–17, 36, 37]. Thus, we speculate that in vivo
inhibition of angiogenesis by curcumin may be a conse-Basement membrane degradation by proteases is an
essential step for both tumor cell invasion and angiogen- quence of multiple effects against several targets re-
quired for angiogenesis, including APN. Our resultsesis. APN, as a matrix degrading zinc metallopeptidase,
is crucially involved in tumor cell invasion and angiogen- demonstrate aminopeptidase N as a new direct binding
target of curcumin for its antiangiogenic activity. Theseesis [3–7]. Thus, the inhibition of APN activity was re-
garded as sufficient to suppress angiogenesis [6, 7]. data will help to decipher the mode of actions of this
clinically promising agent.Our data showed that curcumin strongly inhibited both
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of APN-negative tumor cells, suggesting that the anti-
invasive activity of curcumin against tumor cells is
attributable to the inhibition of APN. Thus, our study
reveals that curcumin is a novel irreversible inhibitor
of APN and provides a new mode of action of curcumin
for its antiangiogenic activity. Furthermore, this study
strongly supports the idea that the targeted inhibition
of APN activity is a novel approach to prevent tumor
angiogenesis and metastasis. It may also be possible
to develop potent derivatives of curcumin, since APN
has been defined as the functional target of the com-
pound for antiangiogenesis.
Experimental Procedures
Materials
Aminopeptidase N (APN), curcumin, bestatin, and ala-7-amido-
4-methylcoumarin were purchased from Sigma (St. Louis, MO).
WM15 (mouse monoclonal anti-human APN) was obtained from BD
PharMingen (San Diego, CA). Sensor chip CM5 and the Amine Cou-
pling Kit were obtained from BIAcore AB (Uppsala, Sweden). Basic
fibroblast growth factor (bFGF) was obtained from Upstate Biotech-
nology (Lake Placid, NY), cell culture media from Life Technology
(Grand Island, NY), Matrigel from Collaborative Biomedical Products
(Bedford, MA), Transwell plates from Corning Costar (Cambridge,
MA), Complete Mini protease inhibitor cocktail from Roche (Mann-
heim, Germany), and Microcon-YM30 from Millipore (Bedford, MA).
Hydrazinocurcumin, an inactive analog of curcumin, was prepared
by a chemical modification of curcumin as reported previously [38].
Cell Culture and Growth Assay
Early passages (4–8 passages) of human umbilical vein endothelial
Figure 7. Curcumin Inhibits Tumor Invasion of APN-Positive Cells cells (HUVECs) were kindly provided by Dr. Y.G. Kwon at Kangwon
but Does Not Affect an APN-Negative Cell Line National University. HUVECs were grown in Medium-199 supple-
(A) Effect of curcumin on C8161 and MDA-MB-231 cell invasion. mented with 20% fetal bovine serum (FBS), 5 units/l of heparin,
The number of cells that invaded was determined using a micro- and 1% bFGF. C8161, HT1080, MCF-7, and MDA-MB-231 cells were
scope, and the data are presented as the average number of invaded maintained in DMEM, and B16/BL6, HT29, and HCT116 cells
cells. The invasiveness of each cell line without curcumin treatment were grown in RPMI1640 containing 10% FBS. The proliferation
was used as a normalization control (100%). *, p 	 0.003 versus of HUVECs was measured using a 3-(4,5-dimethylthiazol-2-yl)-
C8161 control; #, p	 0.0002 versus MDA-MB-231 cells treated with 2,5-diphenyltetrazolium bromide (MTT) assay, and the cytotoxicity was
10 M curcumin. assessed using trypan blue staining as described previously [38].
(B) Effects of curcumin and bestatin on bFGF-induced tumor inva-
sion of three APN-positive cell lines. The invasiveness of each cell Assay of APN Activity
line in serum-free media was used as a normalization control (100%). The activity of APN was determined according to the method de-
Each value represents mean  SE from three independent experi- scribed by Saiki et al. [4]. Briefly, the enzyme substrate, ala-7-amido-
ments. *, p 	 0.0006; #, p 	 0.001 versus bFGF-stimulated HT1080 4-methylcoumarin (0.1 mM), was added to phosphate buffered sa-
control. line (PBS) with or without inhibitors. The reaction was initiated by
adding an enzyme solution (final concentration, 2  104 unit) and
continued in a darkroom at 37C. After 1 hr, the mixture was centri-
fuged and the supernate was collected for the measurement ofSignificance
fluorescence using a FL600 microplate fluorescence reader (Bio-
Tek Instrument Inc, Winooski, VT) at the excitation and emissionAngiogenesis is the formation of new blood vessels
wavelengths of 360 and 460 nm, respectively. For in vivo cell-based
from preexisting vasculature. This process is essential enzyme assay, cells (2  105) were seeded in each well of a 24-well
for tissue growth, wound repair, tumor growth, and culture plate, and after incubation for 24 hr culture medium in each
metastasis. APN is a membrane-bound, zinc-depen- well was replaced with 500 l of PBS. Substrates (0.1 mM) were
added directly into each well with or without inhibitors, and the platedent metalloproteinase that is believed to play a key
was incubated in a darkroom at 37C for 1 hr. The supernate fromrole in tumor invasion and angiogenesis. Accordingly,
each well was collected, and enzyme activity was determined asAPN is considered an important therapeutic target for
described above.
tumor angiogenesis and metastasis. The present
study demonstrates for the first time that curcumin, a Reversibility of APN Inhibition
potent chemopreventive agent in phase I clinical trials, Purified APN was incubated with or without test compounds at 4C
for 2 hr. Each reaction solution was then applied to a Microcon-binds to APN and irreversibly inhibits its activity. The
YM30 filter and centrifuged for 10 min at 10,000 g. The residualdirect interaction between curcumin and APN was
enzyme solution retained in the upper part of the Microcon-YM30confirmed by in vitro and in vivo assays. Furthermore,
filter was resuspended in PBS and examined for APN activity. Eachcurcumin and other known APN inhibitors strongly
resuspended enzyme solution was further applied to a Microcon-
inhibited APN-positive tumor cell invasion and basic YM30 filter, and the residual enzyme activity was measured. The
fibroblast growth factor-induced angiogenesis. How- filtration steps were performed three times. At each step, the APN
activity of drug-untreated control was normalized to 100%, andever, curcumin did not significantly inhibit the invasion
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drug-treated enzyme activity was expressed as a percentage of observed under a microscope. Retinoic acid was used as a positive
control.inhibition versus each control.
RNA Preparation and Reverse Transcriptase-PolymeraseSPR Analysis
Chain ReactionPurified porcine APN was covalently linked to a CM5 sensor chip with
Total cellular RNA was reversely transcribed by Molony murine leu-the Amine Coupling Kit. The surface matrix was activated by a 7 min
kemia virus reverse transcriptase (Life Technologies, Rockville, MD)injection of an aqueous solution of 0.2 M N-ethyl-N-(3-diethyl-
using Oligo-d(T)15 primers (Life Technologies). To determine theaminopropyl)-carbodiimide (EDC) and 50 mM N-hydroxysuccinimide
mRNA content of APN in each cell line, a standard PCR was performed(NHS). Then, APN (100 g/ml) diluted in sodium acetate buffer (pH
using 5-CCTTCAACCTGGCCAGTGC-3 and 5-CGTCTTCTCCAG4.5) was injected into the sensor cells. All coupling reactions were
GGCTTGCTCC-3 as primers. The PCR products were resolvedperformed at a flow rate of 5l/min. Remaining N-hydroxysuccinimide-
through 1% agarose gel electrophoresis and visualized by ethidiumester groups were inactivated by injection of 1.0 M ethanolamine-
bromide staining. The mRNA level of either -actin or glyceralde-HCl (pH 8.5) for 10 min. For the binding analysis, samples in the
hyde-3-phosphate dehydrogenase (GAPDH) was used as an internalrunning buffer (10 mM HEPES [pH 7.4], 150 mM NaCl, and 3 mM
control.EDTA) containing 5% DMSO were injected at a flow rate of 30 l/
min. Association and dissociation curves were obtained on a BIA-
Statistical Analysiscore 3000. The surface of the sensor chip was regenerated by injec-
Results are expressed as the mean standard error (SE). Student’stion of 10 l of the regeneration buffer (10 mM NaCl and 0.1 mM
t test was used to determine statistical significance between controlNaOH). The surface plasmon resonance (SPR) response curves were
and test groups. A p value of 	0.05 was considered statisticallyanalyzed with BIAcore Evaluations software, version 3.1. The disso-
significant.ciation rate constant (kd) was determined from a plot of ln(R0/R)
versus time, with R being the surface plasmon resonance signal at
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HUVECs were harvested using PBS containing 2 mM EDTA and
Referencestreated with curcumin or hydrazinocurcumin. After washing with
PBS, the cells were fixed with 4% paraformaldehyde for 30 min at
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C. After washing with fluorescence activated cell sorting (FACS)
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J. 231, 445–449.beled cells were washed with FACS buffer and analyzed on a Coulter
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Clin. Exp. Metastasis 13, 337–344.
In Vitro Endothelial Cell Tube Formation Assay
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